Literature DB >> 9873610

Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.

M Llinàs-Brunet1, M Bailey, R Déziel, G Fazal, V Gorys, S Goulet, T Halmos, R Maurice, M Poirier, M A Poupart, J Rancourt, D Thibeault, D Wernic, D Lamarre.   

Abstract

Replacement of the C-terminal carboxylic acid functionality of peptide inhibitors of hepatitis C virus (HCV) NS3 protease (complexed with NS4A peptide cofactor) by activated carbonyl groups does not produce any substantial increase in potency. These latter inhibitors also inhibit a variety of other serine and cysteine proteases whereas the carboxylic acids are specific. Norvaline was identified as a chemically stable replacement for the P1 residue of Ac-DDIVPC-OH which was also compatible with activated carbonyl functionalities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9873610     DOI: 10.1016/s0960-894x(98)00480-6

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  Combined X-ray, NMR, and kinetic analyses reveal uncommon binding characteristics of the hepatitis C virus NS3-NS4A protease inhibitor BI 201335.

Authors:  Christopher T Lemke; Nathalie Goudreau; Songping Zhao; Oliver Hucke; Diane Thibeault; Montse Llinàs-Brunet; Peter W White
Journal:  J Biol Chem       Date:  2011-01-26       Impact factor: 5.157

2.  Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.

Authors:  Peter W White; Montse Llinàs-Brunet; Ma'an Amad; Richard C Bethell; Gordon Bolger; Michael G Cordingley; Jianmin Duan; Michel Garneau; Lisette Lagacé; Diane Thibeault; George Kukolj
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

3.  In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.

Authors:  Caterina Trozzi; Linda Bartholomew; Alessandra Ceccacci; Gabriella Biasiol; Laura Pacini; Sergio Altamura; Frank Narjes; Ester Muraglia; Giacomo Paonessa; Uwe Koch; Raffaele De Francesco; Christian Steinkuhler; Giovanni Migliaccio
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.

Authors:  Diane Thibeault; Christiane Bousquet; Rock Gingras; Lisette Lagacé; Roger Maurice; Peter W White; Daniel Lamarre
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 5.  Overview of HCV Life Cycle with a Special Focus on Current and Possible Future Antiviral Targets.

Authors:  Nathalie Alazard-Dany; Solène Denolly; Bertrand Boson; François-Loïc Cosset
Journal:  Viruses       Date:  2019-01-06       Impact factor: 5.048

6.  A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.

Authors:  Subramanyam Vankadara; Monique Danielle Dawson; Jia Yi Fong; Qin Yao Oh; Qi An Ang; Boping Liu; Hong Yun Chang; Judice Koh; Xiaoying Koh; Qian Wen Tan; Joma Joy; Cheng San Brian Chia
Journal:  ACS Med Chem Lett       Date:  2022-07-19       Impact factor: 4.632

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.